View Item 

Show simple item record

Letter: hepatocellular carcinoma risk in patients with non‐selective beta blockers—authors’ reply
dc.contributor.authorWijarnpreecha, Karn
dc.contributor.authorLi, Fang
dc.contributor.authorDang, Yifang
dc.contributor.authorTaner, C. Burcin
dc.contributor.authorYang, Liu
dc.contributor.authorTao, Cui
dc.date.accessioned2021-10-05T15:05:59Z
dc.date.available2022-11-05 11:05:58en
dc.date.available2021-10-05T15:05:59Z
dc.date.issued2021-10
dc.identifier.citationWijarnpreecha, Karn; Li, Fang; Dang, Yifang; Taner, C. Burcin; Yang, Liu; Tao, Cui (2021). "Letter: hepatocellular carcinoma risk in patients with non‐selective beta blockers—authors’ reply." Alimentary Pharmacology & Therapeutics (8): 1095-1096.
dc.identifier.issn0269-2813
dc.identifier.issn1365-2036
dc.identifier.urihttps://hdl.handle.net/2027.42/170219
dc.publisherWiley Periodicals, Inc.
dc.titleLetter: hepatocellular carcinoma risk in patients with non‐selective beta blockers—authors’ reply
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelOtolaryngology
dc.subject.hlbsecondlevelPharmacy and Pharmacology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/170219/1/apt16598_am.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/170219/2/apt16598.pdf
dc.identifier.doi10.1111/apt.16598
dc.identifier.sourceAlimentary Pharmacology & Therapeutics
dc.identifier.citedreferenceWijarnpreecha K, Li F, Taner CB, Yang L, Tao C. Editorial: when to start carvedilol in cirrhosis‐time to reconsider? Authors’ reply. Aliment Pharmacol Ther. 2021; 54 ( 5 ): 728 ‐ 729.
dc.identifier.citedreferenceGarcia‐Tsao G, Abraldes JG, Berzigotti A, Bosch J. Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. Hepatology. 2017; 65 ( 1 ): 310 ‐ 335.
dc.identifier.citedreferenceRodrigues SG, Mendoza YP, Bosch J. Beta‐blockers in cirrhosis: evidence‐based indications and limitations. JHEP Rep. 2020; 2: 100063.
dc.identifier.citedreferenceHuang DQ, Nguyen MH. Letter: hepatocellular carcinoma risk in patients with non‐selective beta blockers. Aliment Pharmacol Ther. 2021; 54: 1093 – 1094.
dc.identifier.citedreferenceWijarnpreecha K, Li F, Xiang Y, et al. Nonselective beta‐blockers are associated with a lower risk of hepatocellular carcinoma among cirrhotic patients in the United States. Aliment Pharmacol Ther. 2021; 54: 481 ‐ 492.
dc.identifier.citedreferenceBiggins SW, Kim WR, Terrault NA, et al. Evidence‐based incorporation of serum sodium concentration into MELD. Gastroenterology. 2006; 130: 1652 ‐ 1660.
dc.identifier.citedreferenceFreitas ACTd, Rampim AT, Nunes CP, Coelho JCU. Impact of meld sodium on liver transplantation waiting list. Arq Bras Cir Dig. 2019; 32 ( 3 ): e1460.
dc.working.doiNOen
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
apt16598_am.pdf
Size:
135.1KB
Format:
PDF
View/Open
Name:
apt16598.pdf
Size:
191.9KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.